We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+24.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$498M
AUM Growth
+$258M
Cap. Flow
+$49.1M
Cap. Flow %
9.86%
Top 10 Hldgs %
69.52%
Holding
145
New
57
Increased
20
Reduced
22
Closed
41

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$31.2M
2
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$6.99M
3
MRNA icon
Moderna
MRNA
+$3.94M
4
XERS icon
Xeris Biopharma Holdings
XERS
+$3.78M
5
MTVA
MetaVia Inc
MTVA
+$3.18M

Top Sells

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$2.89M
2
ENLV icon
Enlivex Ltd
ENLV
+$2.31M
3
NOVN
Novan, Inc. Common Stock
NOVN
+$2.11M
4
OTLK icon
Outlook Therapeutics
OTLK
+$1.94M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 11.32%
2 Industrials 0.26%
3 Technology 0.12%
4 Consumer Discretionary 0.09%
5 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SOLY
51
DELISTED
Soliton, Inc.
SOLY
$800K 0.16%
+102,891
New +$1.01M
NVCN
52
DELISTED
Neovasc Inc.
NVCN
$776K 0.16%
+13,041
New +$813K
MBIO icon
53
Mustang Bio
MBIO
$4.78M
$747K 0.15%
+313
New +$732K
IONS icon
54
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$731K 0.15%
+124
New +$6.9K
AVGR
55
DELISTED
Avinger, Inc. Common Stock
AVGR
$676K 0.14%
7,278
+5,383
+284% +$610K
IMUX icon
56
Immunic
IMUX
$182M
$642K 0.13%
+5,301
New +$539K
GNCA
57
CALL
DELISTED
Genocea Biosciences, Inc.
GNCA
$489K 0.1%
2,126
+925
+77% +$2.13K
AUPH icon
58
CALL
Aurinia Pharmaceuticals
AUPH
$1.92B
$453K 0.09%
279
-30
-10% -$480
AVEO
59
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$450K 0.09%
87,319
-24,836
-22% -$157K
YTRA icon
60
Yatra Online
YTRA
$54.7M
$441K 0.09%
+650,000
New +$699K
TRIL
61
PUT
DELISTED
Trillium Therapeutics Inc.
TRIL
$426K 0.09%
527
+76
+17% +$470
AUPH icon
62
Aurinia Pharmaceuticals
AUPH
$1.92B
$406K 0.08%
25,000
-17,500
-41% -$280K
GNPX icon
63
Genprex
GNPX
$4.05M
$372K 0.07%
+3
New +$367K
CYTK icon
64
CALL
Cytokinetics
CYTK
$10.8B
$370K 0.07%
+157
New +$2.94K
AGPU
65
Axe Compute Inc
AGPU
$83.5M
$367K 0.07%
+745
New +$348K
PHAS
66
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$354K 0.07%
76,970
-30,607
-28% -$136K
ATNM icon
67
Actinium Pharmaceuticals
ATNM
$27.2M
$342K 0.07%
32,410
+11,682
+56% +$88.5K
ORMP icon
68
PUT
Oramed Pharmaceuticals
ORMP
$171M
$335K 0.07%
949
-860
-48% -$2.89K
ATXS
69
PUT
DELISTED
Astria Therapeutics
ATXS
$306K 0.06%
+79
New +$2.81K
GNCA
70
DELISTED
Genocea Biosciences, Inc.
GNCA
$288K 0.06%
125,312
-314,962
-72% -$725K
DOMH icon
71
Dominari Holdings
DOMH
$54.5M
$281K 0.06%
+20,125
New +$252K
PLUR icon
72
Pluri
PLUR
$18.1M
$263K 0.05%
3,712
-20,294
-85% -$1.33M
IMNN icon
73
CALL
Imunon
IMNN
$6.43M
$243K 0.05%
+3
New +$1.3K
XBI icon
74
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$241K 0.05%
+2,150
New +$212K
BPTH
75
DELISTED
Bio-Path Holdings Inc
BPTH
$227K 0.05%
2,250
-5,465
-71% -$567K
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q2 2020 Portfolio in Review

As of Q2 2020, Sabby Management held 145 positions worth $498M, up 107% from $241M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Sabby Management deployed $49.1M of net new capital in Q2 2020, opening 57 new positions and adding to 20 existing holdings. Its largest new stake was Biogen: 103,902 shares worth $27.8M.

By sector, the portfolio is most concentrated in Healthcare at 11% of assets, up from 7.3% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Enlivex Ltd, an estimated $2.31M trimmed.

  • Sabby Management's largest Q2 2020 buy was Biogen: 103,902 shares worth $27.8M.
  • Sabby Management added most to State Street Health Care Select Sector SPDR ETF in Q2 2020, an estimated $6.99M increase.
  • Sabby Management's biggest Q2 2020 reduction was Enlivex Ltd, cutting an estimated $2.31M.
  • Sabby Management fully exited SPDR Gold Trust in Q2 2020, selling an estimated $2.89M.
  • Sabby Management's ten largest holdings make up 70% of its $498M portfolio in Q2 2020.
  • Sabby Management opened 57 new positions and closed 41 in Q2 2020.
  • Sabby Management's portfolio value rose 107% quarter-over-quarter to $498M.

Based on Sabby Management's 13F filing for Q2 2020, filed 14 Aug 2020.